{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.41","value":"0.11"},{"groupId":"OG001","spread":"0.16","value":"0.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected to evaluate the biochemistry parameter PT/INR. Change from Baseline was defined as the value of Baseline minus from the End of study visit. Baseline was defined as Day 1.","dispersionType":"Standard Deviation","groups":[{"description":"The eligible participants in this arm received 5 g of SRT501, oral suspension every morning at the same time approximately 15-30 minutes following consumption of breakfast) on all dosing days, for 20 consecutive days in a 21-day cycle for a maximum period of 12 cycles. There was no time between the cycles i.e Day 1 of a cycle was started on the day following Day 21 of the previous cycle. SRT501 was not administered on Day 21 of each cycle.","id":"OG000","title":"SRT501 Monotherapy"},{"description":"The eligible participants in this arm received an intravenous solution of Bortezomib at 1.3 mg/m\\^2 in conjunction with SRT501 (5.0 g/day) daily dosing. Bortezomib was administered prior to breakfast and SRT501 administration, on Day 1, 4, 8 and 11 in every 21 day cycle. It was given as per the local institution's guidelines and standards of care.SRT501 + Bortezomib, is a subset of arm SRT501 monotherapy.","id":"OG001","title":"SRT501 + Bortezomib"}],"paramType":"MEAN","populationDescription":"Safety Population. Only those participants available at the particular timepoints were analyzed","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and End of Study assessments/follow-up approximately 28 days (+/- 7 days) following the last dose of SRT501 or SRT501 and bortezomib (approximately 280 days)","title":"Change From Baseline in Biochemistry: Prothrombin Time (PT)/ International Normalized Ratio (INR)","type":"PRIMARY","unitOfMeasure":"Ratio of PT/INR"}